[The effect of serotonin on the cytotoxic activity of natural killer lymphocytes in patients with the first episode of endogenous psychosis]. 2011

E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova

Authors studied the level of cytotoxic activity of natural killer lymphocytes (NKCA) and the effect of monocytes, serotonin, rate of serotonin reuptake by lymphocytes and psychotropic therapy on NKCA levels in 59 male patients, aged 18-30 years, with the first episode of attack-like progressive schizophrenia (33 patients) and schizoaffective psychosis (26 patients). All patients were examined at baseline, 4 and 8 weeks after the beginning of treatment with haloperidol and clozapine. Before the treatment, the decrease of NKCA was found in a half of patients compared to controls. In other patients, the NKCA levels were high and did not differ from those in controls. The treatment resistance was estimated as 70,6% in patients with schizophrenia with initially low NKCA levels and 30,8% in patients with schizoaffective psychosis with initially low NKCA levels. During the treatment, the initially high NKCA level decreased while the initially low level increased but remained lower compared to controls. These changes suggest the active reaction from the immune system of the patient to treatment with neuroleptics. The changes of NKCA values during the treatment were reciprocally related to the maximal rate of serotonin reuptake by lymphocytes. Serotonin added to the cell culture in vitro normalized the NKCA level in cultures with- and without monocytes. This effect was revealed in both pathologies only in responders, regardless of the presence or absence monocytes, that may be explained by the presence of active serotonin receptors on the NK cell surface in these patients.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
August 1990, Brain research,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
September 2021, Molecular psychiatry,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
January 2012, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
January 1985, Cancer research,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
March 2012, Archives of toxicology,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
June 1985, Japanese journal of clinical oncology,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
January 1989, Leukemia research,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
January 1983, Nature,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
December 2020, Andrologia,
E F Vasil'eva, and G I Koliaskina, and O S Brusov, and M I Faktor, and V G Kaleda, and N A Barkhatova, and E D Bogdanova
January 2012, Journal of affective disorders,
Copied contents to your clipboard!